Q1 Earnings Estimate for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Research analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for shares of Arvinas in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.50). The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.66) EPS and FY2027 earnings at $1.77 EPS.

A number of other research firms have also recently commented on ARVN. Wedbush reiterated an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. BTIG Research initiated coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price for the company. Barclays lowered their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Oppenheimer increased their price objective on Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.58.

Arvinas Stock Down 1.6 %

Shares of NASDAQ ARVN opened at $17.67 on Friday. The stock’s 50 day moving average price is $19.04 and its 200-day moving average price is $23.28. The company has a market capitalization of $1.21 billion, a PE ratio of -3.78 and a beta of 1.88. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter in the previous year, the company earned ($2.53) EPS.

Hedge Funds Weigh In On Arvinas

Several hedge funds have recently bought and sold shares of ARVN. Vanguard Group Inc. lifted its stake in Arvinas by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock worth $135,389,000 after purchasing an additional 56,561 shares in the last quarter. FMR LLC raised its position in shares of Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after buying an additional 204,317 shares in the last quarter. JPMorgan Chase & Co. grew its position in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after buying an additional 367,343 shares in the last quarter. New Leaf Venture Partners L.L.C. increased its stake in Arvinas by 10.5% in the 4th quarter. New Leaf Venture Partners L.L.C. now owns 1,585,721 shares of the company’s stock worth $30,398,000 after acquiring an additional 151,000 shares during the last quarter. Finally, Braidwell LP raised its holdings in shares of Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after acquiring an additional 767,242 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.